Daring To Make A Difference COMPANY PRESENTATION September 2020 Prevance FORWARD-LOOKING STATEMENTS / SAFE HARBOR / MARKET DATA This presentation contains forward-looking statements, including forward-statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics and outlook; the growth of markets for global neuromodulators, dermal fillers and aesthetics fintech platforms; the process and timing of, and ability to complete, current and an ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Jeanie Herbert - Head, Investor Relations & Corporate Communications Mark Foley - President & Chief Executive Officer Dustin Sjuts - Chief Commercial Officer, Aesthetics & Therapeutics Toby Schilke - Chief Financial Officer Abhay Joshi - Chief Operating Officer & President of R&D & Product Operations Conference Call Participants Terence Flynn - Goldman Sachs Stacy Ku - Cowen & Company Dav ...

| --- | --- | --- | |--------------------------------|-------|-------| | | | | | | | | | | | | | Daring To Make A Difference | | | | COMPANY PRESENTATION JUNE 2020 | | | This presentation contains forward-looking statements, including forward-statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics and outlook; the process and timing of, and ability to complete, current and anticipated future clinical development of our investigatio ...

Financial Data and Key Metrics Changes - As of March 31, 2020, the company reported cash, cash equivalents, and short-term investments of $511.3 million, sufficient to fund operations into 2023 [38] - Revenue for Q1 2020 was $58,000, primarily from the Mylan collaboration, with operating expenses of $61 million, including a one-time noncash charge of $11.2 million related to in-process research and development [39][40] - The company expects 2020 GAAP operating expenses to be at the lower end of the previously announced guidance of $270 million to $280 million, with non-GAAP operating expenses projected at $220 million to $230 million [41] Business Line Data and Key Metrics Changes - The company is preparing for the launch of its FDA-approved RHA dermal filler portfolio in Q3 2020, with a PDUFA date for DaxibotulinumtoxinA for Injection set for November 25, 2020 [11][33] - The launch of RHA fillers was shifted by one quarter due to COVID-19, but the company remains optimistic about the timing coinciding with a more stable market environment [12][22] Market Data and Key Metrics Changes - The U.S. aesthetic neuromodulator market shrank by 5% in 2009 but returned to growth quickly, indicating resilience in the market [17] - The company anticipates a significant slowdown in aesthetic procedures in Q2 2020, followed by a modest recovery in Q3 and a return to growth in Q4 [20] Company Strategy and Development Direction - The company aims to launch two novel product lines, RHA fillers and DaxibotulinumtoxinA, targeting a premium market segment [14][30] - The strategy includes a phased rollout approach and a focus on virtual education and engagement programs to support healthcare professionals during the pandemic [15][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial and operational strength despite the challenges posed by COVID-19, highlighting a catalyst-rich year ahead [11][13] - The management noted that many practices anticipate pent-up demand for aesthetic procedures as they begin to reopen [16][20] Other Important Information - The company has implemented a COVID-19 preparedness plan and has contributed personal protective equipment to local hospitals [9][10] - The company is in discussions with Mylan regarding a biosimilar to BOTOX, with a response expected by the end of May [37] Q&A Session Summary Question: Update on TEOXANE manufacturing and inventory levels - TEOXANE's manufacturing facility has reopened, and the company is confident in the supply for the Q3 launch [46] Question: Commercial preparation status and cost structure - The company has made significant progress in commercial preparations, with a focus on targeted physician accounts and a limited number of sales representatives [49][50] Question: Potential for opportunistic business development - The company remains disciplined in its approach to acquisitions, focusing on assets that add value while maintaining a strong cash position [54][56] Question: Impact of RHA launch timing on strategy - The RHA launch timing has not changed the overall strategy, and the company continues to prepare for a successful launch [57][58] Question: Plans for DTC marketing and timing - The company plans to focus on physician training and outcomes before implementing direct-to-consumer marketing strategies [79] Question: Opportunities for aggressive launch strategy - The company believes in establishing a strong foundation with physicians before accelerating the launch, while also recognizing the potential benefits of a longer-acting product in the current environment [84][86]

1 Daring to Make a Difference Company Presentation March 2020 『·revance Forward-Looking Statements / Safe Harbor / Market Data 2 This presentation contains forward-looking statements, including forward-statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics and outlook; the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational product candidates, including anticip ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2019 Results Earnings Conference Call February 24, 2020 4:30 AM ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Mark Foley - President, Chief Executive Officer Dustin Sjuts - Chief Commercial Officer of Aesthetics & Therapeutics Toby Schilke - Chief Financial Officer Abhay Joshi - Chief Operating Officer, President of R&D and Product Operations Conference Call Participants Annabel Samimy - Stifel Ken Cacc ...

DAXI AESTHETICS - The global facial aesthetics neuromodulator opportunity is approximately $2.2 billion[21] - Over 7 million neuromodulator procedures are performed annually in the U S[21] - In SAKURA 1, 73 6% of subjects achieved ≥ 2-point composite response vs 0% with placebo[27] - In SAKURA 2, 74 0% of subjects achieved ≥ 2-point composite response vs 1% with placebo[27] NEUROMODULATOR MARKET - The global neuromodulator market is currently valued at $5 1 billion[15] - Facial aesthetics account for 44% of the global neuromodulator market[15] - Therapeutics account for 56% of the global neuromodulator market[17] - The global neuromodulator market is projected to reach $9 7 billion by 2027[16] TEOXANE Partnership - Revance has an exclusive U S distribution agreement for TEOXANE's RHA dermal fillers[47] - The U S filler market is valued at $1 1 billion[47] - The U S HA filler market is growing at a CAGR of 10% and is projected to reach $2 1 billion in sales by 2025[51] DAXI THERAPEUTICS - The global market opportunity for therapeutic indications of botulinum toxin is $2 5 billion[38]

Daring to Make a Difference Investor presentation NASDAQ: RVNC NOVEMBER 2019 Forward-Looking Statements / Safe Harbor / Market Data This presentation contains forward-looking statements, including forward-statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics, the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational product candidates, including anticipated near ...

Financial Data and Key Metrics Changes - The company ended Q3 2019 with cash, cash equivalents, and short-term investments of $209 million, excluding a $5 million milestone payment from Mylan expected in Q4 2019 [18] - Revenue for Q3 2019 was $46,000 from the Mylan collaboration, with operating expenses of $42.6 million, and non-GAAP operating expenses of $37.5 million [19][20] - The company maintained its 2019 guidance, expecting GAAP operating expenses between $173 million and $185 million [20] Business Line Data and Key Metrics Changes - The company is focused on the commercialization of DaxibotulinumtoxinA (DAXI) in the aesthetic market and has plans for a Biologics License Application (BLA) submission by the end of November 2019 [10][12] - DAXI is positioned as a long-acting neuromodulator, with clinical trials showing exceptional response rates and a long duration of effect [11][17] Market Data and Key Metrics Changes - The global therapeutic market is valued at $2.5 billion, with DAXI expected to capture significant market share due to its differentiated long-acting profile [15][38] - The U.S. facial aesthetics market is described as a billion-dollar market, with DAXI targeting the majority of neuromodulator use in facial lines [14] Company Strategy and Development Direction - The company aims to successfully launch DAXI in the aesthetics market while unlocking value in the therapeutic space [27] - The management emphasizes the importance of capital allocation and market research to inform their launch strategy [27] - The company is exploring additional therapeutic indications beyond cervical dystonia, including migraine and upper limb spasticity [39] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming BLA submission and the potential approval and launch of DAXI in the second half of 2020 [23] - The company is optimistic about the long-term value of DAXI in both aesthetic and therapeutic markets, highlighting its unique position as the first true innovation in the neuromodulator market in over 30 years [11][12] Other Important Information - The company has made significant progress in its clinical trials, completing enrollment in multiple studies and preparing for data readouts in 2020 [17] - The management team has been strengthened with key hires in the commercial organization to support the launch of DAXI [13][67] Q&A Session Summary Question: Any specific strategic initiatives or plans evolving from the new CEO's perspective? - The CEO indicated no material changes in strategy, focusing on a successful launch in aesthetics and unlocking value in therapeutics [27] Question: What are the chances of DAXI's performance facilitating additional movement disorder indications? - The CEO stated that cervical dystonia will be the first indication, and future submissions will depend on data from ongoing trials [29] Question: How does the company view pricing in the competitive landscape? - The CEO believes DAXI's long duration will allow for premium pricing, differentiating it from short-acting competitors [35] Question: What therapeutic areas are being considered for further exploration? - The CEO confirmed a focus on existing therapeutic categories, with migraine being a significant market of interest [39] Question: What share does the company expect to capture in the market? - The CEO mentioned that over 50% of consumers indicated that a long-acting neuromodulator would influence their decision-making [42] Question: What is the status of the Mylan biosimilar program? - The CEO noted that Mylan has contributed $30 million to the program, with a decision expected by April 2020 [42][49] Question: Will there be updates on the migraine program? - The CEO indicated that trials for the migraine program could potentially start in 2020, but no specific timeline was provided [53] Question: How does the company plan to approach international filings for DAXI? - The COO stated that international filings would begin approximately six months after the U.S. filing [48] Question: What is the company's strategy regarding potential partnerships for international markets? - The CEO mentioned that they are open to out-licensing rights and exploring partnerships for both therapeutic and aesthetic markets [69]

Daring to Make a Difference Investor presentation NASDAQ: RVNC OCTOBER 2019 2 Forward-Looking Statements / Safe Harbor / Market Data This presentation contains forward-looking statements, including forward-statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics, the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational product candidates, including anticipated nea ...